Cancer in pathologically confirmed multiple system atrophy.
Alpha-synuclein
Breast neoplasms
Gamma-synuclein
Multiple system atrophy
Journal
Clinical autonomic research : official journal of the Clinical Autonomic Research Society
ISSN: 1619-1560
Titre abrégé: Clin Auton Res
Pays: Germany
ID NLM: 9106549
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
09
03
2023
accepted:
12
04
2023
medline:
21
8
2023
pubmed:
14
5
2023
entrez:
13
5
2023
Statut:
ppublish
Résumé
The aim of this study was to assess whether cancer occurs with increased frequency in multiple system atrophy (MSA). The pathological hallmark of MSA is glial cytoplasmic inclusions containing aggregated α-synuclein, and the related protein γ-synuclein correlates with invasive cancer. We investigated whether these two disorders are associated clinically. Medical records of 320 patients with pathologically confirmed MSA seen between 1998 and 2022 were reviewed. After excluding those with insufficient medical histories, the remaining 269 and an equal number of controls matched for age and sex were queried for personal and family histories of cancer recorded on standardized questionnaires and in clinical histories. Additionally, age-adjusted rates of breast cancer were compared with US population incidence data. Of 269 cases in each group, 37 with MSA versus 45 of controls had a personal history of cancer. Reported cases of cancer in parents were 97 versus 104 and in siblings 31 versus 44 for MSA and controls, respectively. Of 134 female cases in each group, 14 MSA versus 10 controls had a personal history of breast cancer. The age-adjusted rate of breast cancer in MSA was 0.83%, as compared with 0.67% in controls and 2.0% in the US population. All comparisons were nonsignificant. The evidence from this retrospective cohort found no significant clinical association of MSA with breast cancer or other cancers. These results do not exclude the possibility that knowledge about synuclein pathology at the molecular level in cancer may lead to future discoveries and potential therapeutic targets for MSA.
Identifiants
pubmed: 37178348
doi: 10.1007/s10286-023-00946-w
pii: 10.1007/s10286-023-00946-w
pmc: PMC10529111
mid: NIHMS1915549
doi:
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-458Subventions
Organisme : NINDS NIH HHS
ID : R01 NS089757
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Int J Mol Sci. 2020 Oct 03;21(19):
pubmed: 33023066
Neurology. 2015 Aug 4;85(5):404-12
pubmed: 26138942
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13450-5
pubmed: 10557341
J Neural Transm (Vienna). 2007 Sep;114(9):1161-5
pubmed: 17510732
Exp Neurol. 1999 Dec;160(2):515-22
pubmed: 10619569
J Biol Chem. 2002 Apr 5;277(14):11970-8
pubmed: 11812782
Clin Auton Res. 2020 Jun;30(3):197-205
pubmed: 32232688
Eur Neurol. 2014;71(3-4):99-105
pubmed: 24335185
Exp Ther Med. 2015 May;9(5):1727-1732
pubmed: 26136884
Mov Disord. 2010 Nov 15;25(15):2604-12
pubmed: 20922810
ACS Omega. 2022 Aug 15;7(34):30281-30290
pubmed: 36061735
Cancer. 2000 May 1;88(9):2154-63
pubmed: 10813729
Hum Mol Genet. 2021 Nov 16;30(23):2332-2346
pubmed: 34254125
Clin Cancer Res. 2009 Sep 1;15(17):5485-93
pubmed: 19706805
Acta Neuropathol. 1996;91(2):145-54
pubmed: 8787147
Intern Med. 2022 Dec 1;61(23):3599-3604
pubmed: 35569977
Acta Neuropathol Commun. 2014 Sep 11;2:132
pubmed: 25209836
Int J Cancer. 2007 Sep 15;121(6):1296-305
pubmed: 17534899
Int Rev Cell Mol Biol. 2008;270:225-317
pubmed: 19081538
BMJ Open. 2021 Jul 2;11(7):e046329
pubmed: 34215604
Brain. 2019 Sep 1;142(9):2813-2827
pubmed: 31289815
Cancer Res. 1997 Feb 15;57(4):759-64
pubmed: 9044857
Cell Motil Cytoskeleton. 2001 Aug;49(4):218-28
pubmed: 11746666
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Clin Cancer Res. 2009 Apr 15;15(8):2864-71
pubmed: 19351749
J Neural Transm (Vienna). 2005 Dec;112(12):1605-12
pubmed: 16284906
Am J Pathol. 1999 Oct;155(4):1241-51
pubmed: 10514406
Oncol Rep. 2020 Mar;43(3):827-838
pubmed: 32020216
Neurosci Lett. 2021 Jun 21;756:135964
pubmed: 34022266
Ann Neurol. 2017 Feb;81(2):287-297
pubmed: 28093795
Neoplasma. 2020 May;67(3):707-713
pubmed: 32202903
Biomolecules. 2022 Jan 16;12(1):
pubmed: 35053291
Arch Neurol. 2010 Aug;67(8):970-5
pubmed: 20697047
BMC Cancer. 2016 Sep 05;16:717
pubmed: 27595752
Clin Auton Res. 2018 Apr;28(2):215-221
pubmed: 29313153
Free Radic Res. 2005 Oct;39(10):1119-25
pubmed: 16298737
Cent Nerv Syst Agents Med Chem. 2019;19(1):24-30
pubmed: 30318002
Int J Mol Sci. 2021 Oct 18;22(20):
pubmed: 34681908
Front Aging Neurosci. 2022 Oct 11;14:1010064
pubmed: 36304930
Mov Disord. 2022 Jun;37(6):1131-1148
pubmed: 35445419
Cancer Cell Int. 2020 Jul 10;20:300
pubmed: 32669976
Medicine (Baltimore). 2016 Sep;95(37):e4874
pubmed: 27631256
Neuropathol Appl Neurobiol. 2007 Dec;33(6):615-20
pubmed: 17990994
Mol Med Rep. 2021 Feb;23(2):
pubmed: 33313952
Cell Rep. 2022 Apr 12;39(2):110675
pubmed: 35417693
Front Pharmacol. 2023 Mar 09;14:1136779
pubmed: 36969868
Alzheimers Res Ther. 2014 Oct 27;6(5):73
pubmed: 25580161
Biochemistry. 2012 Jun 12;51(23):4743-54
pubmed: 22620680
J Clin Neurol. 2019 Apr;15(2):135-142
pubmed: 30938106
Med Oncol. 2013;30(3):612
pubmed: 23696021
Hum Mol Genet. 2009 May 15;18(10):1779-94
pubmed: 19246516
NPJ Parkinsons Dis. 2021 Apr 12;7(1):35
pubmed: 33846345
Oncotarget. 2018 Jun 8;9(44):27435-27447
pubmed: 29937996
Mov Disord. 2021 Feb;36(2):340-346
pubmed: 33346940
Front Neurol. 2020 Aug 20;11:898
pubmed: 32973662
Breast Cancer. 2019 Mar;26(2):206-214
pubmed: 30259332
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
Mov Disord. 2022 Apr;37(4):669-683
pubmed: 35122299
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879
Int J Mol Sci. 2021 Sep 18;22(18):
pubmed: 34576255
Mov Disord. 2010 Sep 15;25(12):1953-9
pubmed: 20623770